REFERENCES
- USP DI. 18th Edition, Drug Information for the Health Care Professional Published by the USP Convention Inc., Rockville, MD 1998
- Livingstone P. H. J. Am. Med. Ass. 1966; 196: 1159
- Duvernoy W. F.C. New Eng. J. Med. 1969; 280: 877–879
- Shapiro S. R. New Engl. J. Med. 1969; 280: 1363
- Peterson R. B., Vasquez L. R. J. Am. Med. Ass. 1973; 223: 324
- Frewin D. B. Med. J. Aus. 1978; 2: 497–499
- Lee K. Y., Beilin L. J., Vandongen R. Lancet 1979; 8126: 1110–1111
- Lee K. Y., Beilin L. J., Vandongen R. Med. J. Aust. 1979; 11: 526–6
- Horowitz J. D., Lang W. J., Howes L. G., Fennessy M. R., Christophidis N., Rand M. J., Louios W. J. Lancet 1980; 8159: 60–61
- Smookler S., Bermudez A. J. Ann. Emerg. Med. 1982; 9: 482
- Howrie D. L., Wolfson J. H. J. Pediatr. 1983; 1: 143–145
- Clark J. E., Simon W. A. Drug Intell. Clin. Pharm. 1983; 10: 737–738
- Jack H., Aselton P., Hunter J. R. Lancet 1984; 8384: 1017
- Lake C. R., Quirk R. S. Psch. Clinics of N. Am. 1984; 7: 689–701
- Pentel P. JAMA 1984; 14: 1898–1903
- Mueller S. M., Muller J., Asdell S. M. Stroke 1984; 1: 119–123
- Kikta D. G., Devereaux M. W., Chandar K. Stroke 1985; 3: 510–512
- Pentel P. R., Asinger R. W., Benowitz N. L. Clin. Pharmacol. Ther. 1985; 5: 488–494
- Fallis R. J., Fisher M. Neurology 1985; 3: 405–407
- Stoess A. J., Young G. B., Feasby T. E. Stroke 1985; 4: 734–736
- Paulman P. M., Commers J., Goode D. L. Nebr. Med. J. 1986; 2: 40–41
- Leo P. J., Hollander J. E., Shis R. D., Marcus S. M. Ann. Emerg. Med. 1986; 3: 359–362
- Bale J. F., Jr., Fountain M. T., Shaddy R. Am. J. Dis. Child 1984; 7: 683–685
- Kase C. S., Foster T. E., Reed J. E., Spatz E. L., Girgis G. N. Neurology 1987; 3: 399–404
- Edwards M., Russo L., Harwood-Nuss A. Am. J. Emerg. Med. 1987; 2: 163–164
- Maher L. M., Peterson P. L., Dela-Cruz C. Neurology 1987; 10: 1686
- Glick R., Hoying J., Cerullo L., Perlman S. Neurosurgery 1987; 6: 969–974
- Liebson I., Bigelow G., Griffiths R. R., Funderburk F. R. J. Clin. Pharmacol. 1987; 27: 685–693
- Lake C. R., Chernow B., Zaloga G., Labow J., Quirk R., Hedges S. M. Neuropsychopharmacology 1988; 1: 163–168
- Lake C. R., Masson E. B., Quirk R. S. Pharmacopschiat 1988; 21: 171–181
- Lake C. R., Zaloga G., Clymer R., Quirk R. S., Chernow B. Am. J. Med. 1988; 85: 339–343
- Bravo E. L. Hypertension 1988; 11: 117–110
- Morgan J. P., Funderburk F. R., Blackburn G. L., Noble R. J. Clin. Psychopharmacology 1989; 9: 33–37
- Blackburn G. L., Morgan J. P., Lavin P. T., Noble R., Funderburk F. R., St.Fan N. I. J.A.M.A. 1989; 261: 3267–3272
- Lake C. R., Zaloga G., Bray J., Rosenberg D., Chernow B. Am. J. Med. 1989; 4: 427–432
- Lake C. R., Callant S., Masson E., Miller P. Am. J. Med. 1990; 2: 195–208
- Lake C. R., Rosenberg D., Quirk R. Int. J. Obesity 1990; 14: 575–582
- Morgan J. P., Funderburk F. R. Int. J. Obesity 1990; 14: 569–574
- Lake C. R., Rosenberg D. B., Gallant S., Zologa G., Chernow B. J. Clin. Pharmacol. 1991; 31: 624–635
- Thomas S. H., Clark K. L., Allen R., Smith S. E. Br. J. Clin. Pharmacol 1991; 6: 705–711
- Sloan M. A., Kittner S. J., Rigamonti D. T.R. Price Neurology 1991; 9: 1358–1364
- Morgan J. P., Funderburk F. Am. J. Clin. Nutr. 1992; 55: 206S–210S
- Greenaway F. L. Am. J. Clin. Nutr. 1992; 55: 203S–205S
- Ryu S. J., Lin S. K. J. Formos. Med. Assoc. 1995; 1–2: 53–55
- Chung Y. T., Hung D. Z., Hsu C. P., Yang D. Y., TC W. Chung Hua I Hsueh Tsa Chih (Taipei) 1998; 7: 432–435
- Greenway F., Herber D., Raum W., Morales S. Obes. Res. 1999; 4: 370–378
- Hamilton R. S., Sharieff G. AM. J. Emerg. Med. 2000; 3: 343–345
- Horwitz R. I., Brass L. M., Kernan W. N., Viscoli C. M. Yale University School of Medicine. 2000 May 10
- Anon. Pharmaceutical Journal 11 November 2000; 700–701
- Romero A. J., Rhodes C. T. J. Pharm. Pharmacol. 1993; 45: 258–262
- King J. Med. J. Aust. 1979; 258
- Bernstein E., Diskant B. Am. Emerg. Med. 1982; 11: 311–315
- Silverman H. I., Kregar B. E., Lewis G. P. Curr. Ther. Res. 1980; 28: 185–194
- Goodman R. P., Wright I. T., Barlascani C. D. Clin. Pharmacol. Ther. 1986; 40: 144–147
- Mitchell C. A. Cur. Ther. Res. 1968; 10: 47–53
- Griboff S. I., Silverman H. I. Cur. Ther. Res. 1975; 17: 535–542
- Altschuler S., Conte A. Sebok Int. J. Obesity 1983; 6: 549–556
- Elkins B. R., Spoerke D. G. Vet. Hum. Toxicol. 1983; 25: 81–85
- Pentel P. R., Aaron C., Paya C. Int. J. Obes. 1985; 9: 115–119
- Pentel P. J.A.M.A. 1985; 253: 2492–2493
- Bradley M. H., Raines J. Curr. Ther. Res. 1989; 46: 74–84
- Kroenke K., Omori D. M., Wood J. O., Meier N. J. Ann. Intern. Med. 1989; 111: 1043–1044
- Rhodes C. T. Clin. Res. And Drug Reg. Affairs 2001; 18, In Press
- Adverse Drug Events (GAO-HEHS-00-21) GAO Reporting to Congressional Requesters January 2000
- Adverse Events (GAO-HEHS-00-61). Statement of Dr. Jane Heinrich 3 February 2000
- Pharmacoepidemeology, L. Brian, Strom. Wiley, New York, NY 2000
- Moore T. J., Psaty B., Furberg C. D. J.A.M.A. 1998; 279: 1571–1573
- Rhodes C. T. Clin. Res. And Drug Reg. Affairs 1988; 15: 1–24
- Rhodes C. T. Clin. Res. And Drug Reg. Affairs 2000; 17: 27–34
- Vol. 1 of 5: FDA Nonprescription Drugs Advisory Committee Meeting. Hearing Transcript. October 19, 2000
- Vol. 2 of 5: FDA Supplementary Materials for October 19. 2000 FDA Committee Meeting
- Vol. 3 of 5: FDA Public meeting on the Safety. Effectiveness and Misuse of PPA for OTC Weight Control Use. May 9, 1991, Hearing Transcript
- Vol. 4 of 5: House of Representatives Committee on Small Business Hearing and Background Materials. September 24, 2000
- Vol. 5 of 5: Nonprescription Drugs Manufacturers Association (NDMA) - Statement on the Safety and Efficacy of PPA as an OTC ingredient. October 17, 1990
- Federal Register 1982; 47: 35344–35346
- Federal Register 1983; 48: 52313–52314
- Federal Register 1982; 47: 8466
- Federal Register 1991; 56: 37792
- Federal Register 1982; 48: 8466
- Federal Register 1991; 56: 13295
- Kernan W. N., Viscoli C. M., Brass L. M., Broderick J. P., Brott T., Feldmann E., Morgenstern L. B., Wilterdink J. L., Horwitz R. L. New Eng. J. Med. 2000; 343: 1826–1832
- CHPA Phenylpropanalamine Working Group. Comments on Hemorrhagic Stroke Project Report, May 24 2000 (page 4) Data submitted to Dockets Management Branch (HFA-305) on 24 May 2000
- Letter of 13 June 1993 from Dr. William E. Gilberston of FDA to Dr. William Soller of NDMA
- News Watcher http://www.nandotimes.com/noframes/story 31 January 2001
- Pharmaceutical Journal, 265 641,28 October 2000 and 709, 11 November 2000
- Schessman J. L. Preventive Medicine 1987; 16: 195–210
- Caplan L. Neurology 1988; 38: 624–627
- Kase C. S., Foster T. E., Reed J. E., Spatz E. L., Girgis G. N. Neurology 1987; 37: 337–404
- Glick R., Hoying J., Cerulloand L., Perlman S. Neurosugery 1987; 20: 969–974
- Harrington M., Heller A., Dawson D., Caplan L., Rumbaugh C. Arch. Neurol. 1983; 40: 503–507
- Guidelines for research involving the abuse liability assessment of new drugs Draft 12-2-98. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anesthetic, Critical Care and Addiction Drug Products (HFD0170)
- Brushwood D. B., Abood R. R. Drug Intelligence and Clin. Pharm. 1985; 19: 62–66
- Martin S. American Pharmacy 1991; NS31: 36–40
- Marshall R. P. American Pharmacy 1992; NS32: 64–67
- General Accounting Office Report PEMD 95–12 Pharmacist Controlled Non-prescription Drugs (1995)